{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:30:11Z","timestamp":1770640211827,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Immune Based Ther Vaccines"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1476-8518-5-11","type":"journal-article","created":{"date-parts":[[2007,10,23]],"date-time":"2007-10-23T04:40:27Z","timestamp":1193114427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant"],"prefix":"10.1186","volume":"5","author":[{"given":"Cassandra D","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"O'Loughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank B","family":"Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny W","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie E","family":"Sower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick M","family":"Cirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,22]]},"reference":[{"key":"39_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/clinids\/19.6.1009","volume":"19","author":"FM LaForce","year":"1994","unstructured":"LaForce FM: Anthrax. Clin Infect Dis. 1994, 19: 1009-1013.","journal-title":"Clin Infect Dis"},{"key":"39_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymthe.2004.10.018","volume":"11","author":"K Kasuya","year":"2005","unstructured":"Kasuya K, Boyer JL, Tan Y, Alipui DO, Hackett NR, Crystal RG: Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol Ther. 2005, 11: 237-244. 10.1016\/j.ymthe.2004.10.018.","journal-title":"Mol Ther"},{"key":"39_CR3","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1016\/S0264-410X(01)00197-9","volume":"19","author":"RJ Beedham","year":"2001","unstructured":"Beedham RJ, Turnbull PC, Williamson ED: Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine. 2001, 19: 4409-4416. 10.1016\/S0264-410X(01)00197-9.","journal-title":"Vaccine"},{"key":"39_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","volume":"70","author":"D Kobiler","year":"2002","unstructured":"Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z: Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun. 2002, 70: 544-560. 10.1128\/IAI.70.2.544-550.2002.","journal-title":"Infect Immun"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/iai.65.12.5171-5175.1997","volume":"65","author":"SF Little","year":"1997","unstructured":"Little SF, Ivins BE, Fellows PF, Friedlander AM: Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun. 1997, 65: 5171-5175.","journal-title":"Infect Immun"},{"key":"39_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski LA: Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004, 2: 695-703. 10.1038\/nrmicro974.","journal-title":"Nat Rev Microbiol"},{"key":"39_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3201\/eid0808.010516","volume":"8","author":"A Casadevall","year":"2002","unstructured":"Casadevall A: Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis. 2002, 8: 833-841.","journal-title":"Emerg Infect Dis"},{"key":"39_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1517\/14712598.5.10.1359","volume":"5","author":"A Casadevall","year":"2005","unstructured":"Casadevall A, Pirofski LA: The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther. 2005, 5: 1359-1372. 10.1517\/14712598.5.10.1359.","journal-title":"Expert Opin Biol Ther"},{"key":"39_CR9","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","volume":"38","author":"A Casadevall","year":"1994","unstructured":"Casadevall A, Scharff MD: Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994, 38: 1695-1702.","journal-title":"Antimicrob Agents Chemother"},{"key":"39_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","volume":"21","author":"A Casadevall","year":"1995","unstructured":"Casadevall A, Scharff MD: Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995, 21: 150-161.","journal-title":"Clin Infect Dis"},{"key":"39_CR11","first-page":"135","volume":"11","author":"PB Jahrling","year":"1996","unstructured":"Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, Schmidt JJ, LeDuc JW, Peters CJ: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 1996, 11: 135-140.","journal-title":"Arch Virol Suppl"},{"key":"39_CR12","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1086\/514310","volume":"179 Suppl 1","author":"PB Jahrling","year":"1999","unstructured":"Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, LeDuc JW, Peters CJ: Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999, 179 Suppl 1: S224-S234.","journal-title":"J Infect Dis"},{"key":"39_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","volume":"19","author":"RJ Collier","year":"2003","unstructured":"Collier RJ, Young JA: Anthrax toxin. Annu Rev Cell Dev Biol. 2003, 19: 45-70. 10.1146\/annurev.cellbio.19.111301.140655.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"39_CR14","first-page":"61","volume":"271","author":"DB Lacy","year":"2002","unstructured":"Lacy DB, Collier RJ: Structure and function of anthrax toxin. Curr Top Microbiol Immunol. 2002, 271: 61-85.","journal-title":"Curr Top Microbiol Immunol"},{"key":"39_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","volume":"7","author":"M Moayeri","year":"2004","unstructured":"Moayeri M, Leppla SH: The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol. 2004, 7: 19-24. 10.1016\/j.mib.2003.12.001.","journal-title":"Curr Opin Microbiol"},{"key":"39_CR16","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","volume":"79","author":"SH Leppla","year":"1982","unstructured":"Leppla SH: Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982, 79: 3162-3166. 10.1073\/pnas.79.10.3162.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"39_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.280.5364.734","volume":"280","author":"NS Duesbery","year":"1998","unstructured":"Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998, 280: 734-737. 10.1126\/science.280.5364.734.","journal-title":"Science"},{"key":"39_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1128\/MMBR.68.3.373-402.2004","volume":"68","author":"H Barth","year":"2004","unstructured":"Barth H, Aktories K, Popoff MR, Stiles BG: Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev. 2004, 68: 373-402, table. 10.1128\/MMBR.68.3.373-402.2004.","journal-title":"Microbiol Mol Biol Rev"},{"key":"39_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1086\/367710","volume":"187","author":"BJ Dezube","year":"2003","unstructured":"Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, Burns EM, Dixon JD, O'Loughlin C, Williams LA, Pickering PJ, Crumpacker CS, Gelder FB: A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis. 2003, 187: 500-503. 10.1086\/367710.","journal-title":"J Infect Dis"},{"key":"39_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1310\/1FLN-8KFC-5HEQ-K19J","volume":"5","author":"SL Pett","year":"2004","unstructured":"Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, Emery S, Kaplan E, McPhee DA, McLachlan AJ, Gelder FB, Lewin SR, Liauw W, Williams KM: A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin Trials. 2004, 5: 91-98. 10.1310\/1FLN-8KFC-5HEQ-K19J.","journal-title":"HIV Clin Trials"},{"key":"39_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/01.aids.0000210604.78385.95","volume":"20","author":"EE Verity","year":"2006","unstructured":"Verity EE, Williams LA, Haddad DN, Choy V, O'Loughlin C, Chatfield C, Saksena NK, Cunningham A, Gelder F, McPhee DA: Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS. 2006, 20: 505-515. 10.1097\/01.aids.0000210604.78385.95.","journal-title":"AIDS"},{"key":"39_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1006\/bbrc.2001.5337","volume":"286","author":"N Ahuja","year":"2001","unstructured":"Ahuja N, Kumar P, Bhatnagar R: Rapid purification of recombinant anthrax-protective antigen under nondenaturing conditions. Biochem Biophys Res Commun. 2001, 286: 6-11. 10.1006\/bbrc.2001.5337.","journal-title":"Biochem Biophys Res Commun"},{"key":"39_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1006\/bbrc.2001.4777","volume":"283","author":"V Chauhan","year":"2001","unstructured":"Chauhan V, Singh A, Waheed SM, Singh S, Bhatnagar R: Constitutive expression of protective antigen gene of Bacillus anthracis in Escherichia coli. Biochem Biophys Res Commun. 2001, 283: 308-315. 10.1006\/bbrc.2001.4777.","journal-title":"Biochem Biophys Res Commun"},{"key":"39_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-8518-2-5","volume":"2","author":"R Sawada-Hirai","year":"2004","unstructured":"Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, Alvarez A, Millis D, Morrow PR, Kang AS: Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines. 2004, 2: 5-10.1186\/1476-8518-2-5.","journal-title":"J Immune Based Ther Vaccines"},{"key":"39_CR25","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.1128\/IAI.00712-06","volume":"74","author":"L Vitale","year":"2006","unstructured":"Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK, Keler T: Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun. 2006, 74: 5840-5847. 10.1128\/IAI.00712-06.","journal-title":"Infect Immun"},{"key":"39_CR26","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1016\/j.vaccine.2006.04.065","volume":"24","author":"JE Herrmann","year":"2006","unstructured":"Herrmann JE, Wang S, Zhang C, Panchal RG, Bavari S, Lyons CR, Lovchik JA, Golding B, Shiloach J, Lu S: Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine. 2006, 24: 5872-5880. 10.1016\/j.vaccine.2006.04.065.","journal-title":"Vaccine"},{"key":"39_CR27","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","volume":"69","author":"S Reuveny","year":"2001","unstructured":"Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A, Velan B: Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun. 2001, 69: 2888-2893. 10.1128\/IAI.69.5.2888-2893.2001.","journal-title":"Infect Immun"},{"key":"39_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1067\/mem.2002.129939","volume":"40","author":"SP Bush","year":"2002","unstructured":"Bush SP, Green SM, Moynihan JA, Hayes WK, Cardwell MD: Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann Emerg Med. 2002, 40: 619-624. 10.1067\/mem.2002.129939.","journal-title":"Ann Emerg Med"},{"key":"39_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bjp.0702286","volume":"126","author":"RG Jones","year":"1999","unstructured":"Jones RG, Lee L, Landon J: The effects of specific antibody fragments on the 'irreversible' neurotoxicity induced by Brown snake (Pseudonaja) venom. Br J Pharmacol. 1999, 126: 581-584. 10.1038\/sj.bjp.0702286.","journal-title":"Br J Pharmacol"},{"key":"39_CR30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4269\/ajtmh.1999.61.361","volume":"61","author":"RG Jones","year":"1999","unstructured":"Jones RG, Corteling RL, Bhogal G, Landon J: A novel Fab-based antivenom for the treatment of mass bee attacks. Am J Trop Med Hyg. 1999, 61: 361-366.","journal-title":"Am J Trop Med Hyg"},{"key":"39_CR31","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1128\/JVI.74.4.1614-1622.2000","volume":"74","author":"RA Tripp","year":"2000","unstructured":"Tripp RA, Moore D, Winter J, Anderson LJ: Respiratory syncytial virus infection and G and\/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB\/c mice. J Virol. 2000, 74: 1614-1622. 10.1128\/JVI.74.4.1614-1622.2000.","journal-title":"J Virol"},{"key":"39_CR32","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1128\/IAI.00150-06","volume":"74","author":"J Rivera","year":"2006","unstructured":"Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, Collier RJ, Dadachova E, Casadevall A: A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun. 2006, 74: 4149-4156. 10.1128\/IAI.00150-06.","journal-title":"Infect Immun"},{"key":"39_CR33","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1128\/IAI.72.11.6313-6317.2004","volume":"72","author":"F Brossier","year":"2004","unstructured":"Brossier F, Levy M, Landier A, Lafaye P, Mock M: Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun. 2004, 72: 6313-6317. 10.1128\/IAI.72.11.6313-6317.2004.","journal-title":"Infect Immun"},{"key":"39_CR34","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1128\/IAI.73.12.8362-8368.2005","volume":"73","author":"R Mabry","year":"2005","unstructured":"Mabry R, Rani M, Geiger R, Hubbard GB, Carrion R, Brasky K, Patterson JL, Georgiou G, Iverson BL: Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun. 2005, 73: 8362-8368. 10.1128\/IAI.73.12.8362-8368.2005.","journal-title":"Infect Immun"}],"container-title":["Journal of Immune Based Therapies and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-8518-5-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:16:41Z","timestamp":1630451801000},"score":1,"resource":{"primary":{"URL":"https:\/\/jibtherapies.biomedcentral.com\/articles\/10.1186\/1476-8518-5-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1186\/1476-8518-5-11","relation":{},"ISSN":["1476-8518"],"issn-type":[{"value":"1476-8518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,22]]},"assertion":[{"value":"24 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}